Endocyte (ECYT) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Endocyte (ECYT) Misses Q4 EPS by 1c

Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update

March 10, 2017 8:05 AM EST

WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the fourth quarter ending December 31, 2016, and provided a clinical and business update.

We are pleased to report progress on several aspects of the business during the last several weeks, commented Mike Sherman, president and CEO at Endocyte. The separately announced collaboration with Seattle Childrens Research Institute and Dr. Michael Jensen, an innovator and thought leader in the field of chimeric antigen receptor... More